Treatment:
The diabetic foot ulcer treatment market is segmented based on treatment into Biologics and Therapy Devices. Biologics segment is expected to witness significant growth in the market due to the increasing adoption of advanced biologic therapies for the treatment of diabetic foot ulcers. The therapy devices segment is also anticipated to grow, driven by technological advancements and increasing investment in research and development activities.
Ulcer Type:
The market is further segmented based on ulcer type into Ischemic and Neuropathic ulcers. Ischemic ulcers are caused by poor blood circulation to the foot, leading to tissue damage and delayed wound healing. On the other hand, neuropathic ulcers result from nerve damage, leading to loss of sensation in the foot and increased risk of injury. The prevalence of these ulcer types varies across different regions, influencing the market growth and adoption of specific treatment modalities.
End-use:
Hospitals and Ambulatory Surgical Centers (ASCs) are the main end-users of diabetic foot ulcer treatment products and services. Hospitals account for a significant market share due to the availability of advanced medical facilities, skilled healthcare professionals, and comprehensive treatment options for diabetic foot ulcers. ASCs are gaining popularity among patients seeking outpatient treatment for diabetic foot ulcers, as they offer convenience, cost-effectiveness, and personalized care.